Research Progress of Antibacterial Cyclopeptides

doi:10.13523/j.cb.20181110

China Biotechnology

2018, Vol. 38

Issue (11): 76-83 DOI: 10.13523/j.cb.20181110

Research Progress of Antibacterial Cyclopeptides

Jia-ao GE¹,Chang LIU¹,Jian-gang GONG²,Yan-qin LIU^1,^**(

)

^1. College of Science and Engineering, Agricultural University of Hebei, Cangzhou 061100, China
^2. College of Food Science and Technology, Agricultural University of Hebei, Baoding 071000, China

Download:

HTML

PDF(452KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

In view of the adverse effects of avian bacterial diseases on the healthy development of the poultry industry, there is an urgent need to develop new sensitive antimicrobial agents that improve bacterial resistance so as to achieve the purpose of treating bacterial diseases. Cyclic peptides are candidates for antibacterials because they have more biological activities and medicinal properties than linear peptides. The discovery of natural antibacterial cyclic peptides, the synthesis of antibacterial cyclic peptides and the application status of antibacterial cyclic peptide drugs were mainly reviewed. It is expected to help readers to further understand the research situation of antibacterial cyclic peptides and provide assistance for the development of new antibacterial cyclic peptide drugs.

Key words： Cyclic peptides Antibacterial activity Antibacterial mechanism Bacterial diseases Bacterial drug resistance

Received: 04 June 2018 Published: 06 December 2018

ZTFLH:

Q514+.3

Corresponding Authors: Yan-qin LIU E-mail: liuyqjiang@163.com

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Jia-ao GE
	Chang LIU
	Jian-gang GONG
	Yan-qin LIU

Cite this article:

Jia-ao GE,Chang LIU,Jian-gang GONG,Yan-qin LIU. Research Progress of Antibacterial Cyclopeptides. China Biotechnology, 2018, 38(11): 76-83.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20181110 OR https://manu60.magtech.com.cn/biotech/Y2018/V38/I11/76

Table 1 Comparison of antibacterial cyclic peptide synthesis methods

抗菌环肽名称	来源		抗菌对象		抗菌效果		抗菌机制			开发阶段
短杆菌肽S	从土壤细菌Aneurinibacillu migulanus中提取		治疗革兰氏阳性菌、革兰氏阴性菌及部分真菌引起的感染		表现出强烈的抗菌活性		破坏脂质膜和增强细菌细胞质膜的通透性			已上市
多黏菌素B	由多黏芽孢杆菌产生的一组多肽类抗生素		治疗革兰氏阴性菌(尤其是耐药性革兰氏阴性菌)引起的感染		只对大多数革兰氏阴性杆菌有效		三种说法:①破坏细胞膜;②因羟基自由基的积累破坏细菌DNA;③中和内毒素,抑制内毒素的释放及其活力,进一步达到抑制炎症因子释放			已上市
多黏菌素E	由某些细菌多黏类芽孢杆菌菌株产生的抗生素		治疗大多数革兰氏阴性杆菌引起的感染		只对大多数革兰氏阴性杆菌有效		与多黏菌素B作用机制相同			已上市
万古霉素	从采集Borneo土壤中的微生物发酵产物中分离得到		治疗革兰氏阳性菌引起的感染		对金黄色葡萄球菌、肺炎链球菌等作用强		抑制细胞壁合成			已上市
达托霉素	从玫瑰孢链霉菌(Streptomyces roseosporus)发酵液中提取得到		治疗革兰氏阳性菌引起的复杂皮肤感染和结构性皮肤感染		只对革兰氏阳性菌有杀菌作用		破坏细胞膜			已上市
Cubicin (注射用达托霉素)	由玫瑰孢菌发酵产生的半合成抗生素		治疗由革兰氏阳性病原体引起的皮肤和皮肤结构感染		只对革兰氏阳性菌有杀菌作用		破坏细胞膜			已上市
Nisin	由乳酸乳球菌(Lactococcus lactis)产生的多环类抗菌肽		杀死或抑制引起食品腐败的革兰氏阳性菌		对产生孢子的细菌有很强的抑制作用		破坏细胞质膜			已上市
普那霉素	由始旋链霉菌产生的一种链阳性菌素类抗生素		治疗顽固性革兰氏阳性菌感染的特选药物		对大多数革兰氏阳性菌均具有较强的杀菌活性		抑制蛋白质合成			已上市
抗菌环肽名称		来源		抗菌对象		抗菌效果		抗菌机制	开发阶段
Telavancin		半合成的环脂糖肽类药物		治疗复杂性皮肤及皮肤结构感染/医院获得性感染		对常见皮肤软组织感染病原菌及引起肺炎的革兰氏阳性菌具有突出的体外抗菌活性		细菌细胞壁合成抑制剂	已上市
Dalbavancin		半合成的环脂糖肽类药物		治疗复杂性皮肤及皮肤结构感染		对革兰氏阳性菌具有优良的抗菌活性		细菌细胞壁合成抑制剂	已上市
Oritavancin		半合成的环脂糖肽类药物		治疗革兰氏阳性的皮肤感染		对革兰氏阳性具有抗菌活性		细菌细胞壁合成抑制剂	已上市
POL7080		使用阳离子抗菌肽ProtegrinⅠ作为出发点,对肽库进行迭代修改和筛选		治疗绿脓假单胞菌感染,革兰氏阴性菌感染		具有较强的抗菌活性		LptD同源蛋白抑制剂,抑制外膜的生物合成	Ⅱ期

Table 2 Development status of some antibacterial cyclic peptide drugs


[1]	Ćupić V, TurubatoviĆ L, AntonijeviĆ B , et al. Rational use of drugs in veterinary medicine and food safety. Journal of Hygienic Engineering and Design, 2013,4:20-25.

[2]	Altekruse S F, Cohen M L, Swerdlow D L . Emerging foodborne diseases. Emerging Infectious Diseases, 1997,3(3):285-293. doi: 10.3201/eid0303.970304

[3]	Mor-Mur M, Yuste J . Emerging bacterial pathogens in meat and poultry: An Overview. Food and Bioprocess Technology, 2009,3(1):24-35. doi: 10.1007/s11947-009-0189-8

[4]	Jennings J L, Sait L C, Perrett C A , et al. Campylobacter jejuni is associated with, but not sufficient to cause vibrionic hepatitis in chickens. Vet Microbiol, 2011,149(1-2):193-199. doi: 10.1016/j.vetmic.2010.11.005 pmid: 21112163

[5]	Chaves Hernández A J . Poultry and avian diseases. In: Encyclopedia of agriculture and food systems. Oxford: Academic Press, 2014: 504-520.

[6]	Hoon J S . Cyclic Peptides as therapeutic agents and biochemical tools. Biomolecules & Therapeutics, 2012,20(1):19-26. doi: 10.4062/biomolther.2012.20.1.019 pmid: 3792197

[7]	Borthwick A D . 2, 5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products. Cheminform, 2012,112(7):3641-3716. doi: 10.1002/chin.201238239 pmid: 22575049

[8]	Listed N . Discovery and applications of naturally occurring cyclic peptides. Drug Discovery Today Technologies, 2012,9(1):1-70. doi: 10.2174/157016312799304534

[9]	Gause G F, Brazhnikova M G . Gramicidin S and its use in the treatment of infected wounds. Nature, 1944,154(3918):703. doi: 10.1038/154703a0

[10]	Ovchinnikov Y A, Ivanov V T . ChemInform abstract: conformational states and biological activity of cyclic peptides. Tetrahedron, 1975,31(18):2177-2209. doi: 10.1016/0040-4020(75)80216-X

[11]	Conti E, Stachelhaus T, Marahiel M A , et al. Structural basis for the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S. Embo Journal, 1997,16(14):4174-4183. doi: 10.1093/emboj/16.14.4174 pmid: 9250661

[12]	Velkov T, Roberts K D, Nation R L , et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiology, 2013,8(6):711-724. doi: 10.2217/FMB.13.39 pmid: 3852176

[13]	Yoshino N, Endo M, Kanno H , et al. Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice. PLoS One, 2013,8(4):225-227. doi: 10.1371/journal.pone.0061643 pmid: 3623863

[14]	Schäfer M, Schneider T R, Sheldrick G M . Crystal structure of vancomycin. Structure, 1996,4(12):1509-1515. doi: 10.1016/S0969-2126(96)00156-6

[15]	Nicolaou K C, Boddy C N, Bräse S , et al. Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics. Angewandte Chemie, 1999,30(45):2096-2152. doi: 10.1002/chin.199945336 pmid: 10425471

[16]	Liskamp R M J, Rijkers D T S, Bakker S E . Bioactive macrocyclic peptides and peptide mimics. Modern Supramolecular Chemistry: Strategies for Macrocycle Synthesis, 2008, 1-27. doi: 10.1002/9783527621484.ch1

[17]	Armando G R, Andrew S R, Kamal H . Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections. Infection & Drug Resistance, 2016,9(1):47-58. doi: 10.2147/IDR.S99046 pmid: 27143941

[18]	Kaya S, Yilmaz G, Kalkan A , et al. Treatment of gram-positive left-sided infective endocarditis with daptomycin. Journal of Infection & Chemotherapy, 2013,19(4):698-702. doi: 10.1007/s10156-012-0546-9 pmid: 23299359

[19]	Xing Y, Wang W, Dai S , et al. Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrity. Acta Pharmacologica Sinica, 2014,35(2):211-218. doi: 10.1038/aps.2013.159 pmid: 4651213

[20]	Pogliano J, Pogliano N, Silverman J A . Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. Journal of Bacteriology, 2012,194(17):4494-4504. doi: 10.1128/JB.00011-12

[21]	Huang E, Guo Y, Yousef A E . Draft genome sequence of Paenibacillus sp. strain OSY-SE, a bacterium producing the novel broad-spectrum lipopeptide antibiotic paenibacterin. Journal of Bacteriology, 2012,194(22):6306. doi: 10.1128/JB.01506-12 pmid: 23105053

[22]	Huang E, Guo Y, Yousef A E . Biosynthesis of the new broad-spectrum lipopeptide antibiotic paenibacterin in Paenibacillus thiaminolyticus OSY-SE. Research in Microbiology, 2014,165(3):243-251. doi: 10.1016/j.resmic.2014.02.002 pmid: 24607714

[23]	Qin C, Xu C, Zhang R , et al. On-resin cyclization and antimicrobial activity of Laterocidin and its analogues. Tetrahedron Letters, 2010,51(9):1257-1261. doi: 10.1016/j.tetlet.2009.11.007

[24]	Kaweewan I, Hemmi H, Komaki H , et al. Isolation and structure determination of new antibacterial peptide curacomycin based on genome mining. Asian Journal of Organic Chemistry, 2017,6(12):1838-1844. doi: 10.1002/ajoc.201700433

[25]	Gong A D, Li H P, Yuan Q S , et al. Antagonistic mechanism of iturin A and plipastatin A from Bacillus amyloliquefaciens S76-3 from wheat spikes against Fusarium graminearum. PLoS One, 2015,10(2):0116871. doi: 10.1371/journal.pone.0116871 pmid: 25689464

[26]	Lee Y, Phat C, Hong S C . Structural diversity of marine cyclic peptides and their molecular mechanisms for anticancer, antibacterial, antifungal, and other clinical applications. Peptides, 2017,95:94-105. doi: 10.1016/j.peptides.2017.06.002 pmid: 28610952

[27]	Matsunaga S, Fusetani N, Konosu S . Bioactive marine metabolites VI. structure elucidation of discodermin a, an antimicrobial peptide from the marine sponge discodermia kiiensis. Tetrahedron Letters, 1985,25(45):5165-5168. doi: 10.1016/S0040-4039(01)81553-7

[28]	Oterogonzález A J, Magalhães B S, Garciavillarino M , et al. Antimicrobial peptides from marine invertebrates as a new frontier for microbial infection control. Faseb Journal, 2010,24(5):1320-1334. doi: 10.1096/fj.09-143388 pmid: 20065108

[29]	Eom S H, Kim Y M, Kim S K . Marine bacteria: potential sources for compounds to overcome antibiotic resistance. Applied Microbiology & Biotechnology, 2013,97(11):4763-4773. doi: 10.1007/s00253-013-4905-y pmid: 23640363

[30]	Manoharan R K, Brindha P V, Srigopalram S , et al. Studies on a marine Streptomyces fradiae BW2-7 producing glycopeptide antibiotic Vancomycin effective against skin pathogens. Sch Acad J Biosci, 2014,2(11):746-761.

[31]	Kitani S, Ueguchi T, Igarashi Y , et al. Rakicidin F, a new antibacterial cyclic depsipeptide from a marine sponge-derived Streptomyces sp. Journal of Antibiotics, 2017,71(1):139-141. doi: 10.1038/ja.2017.92 pmid: 28765588

[32]	Kozuma S, Hirotatakahata Y, Fukuda D , et al. Identification and biological activity of ogipeptins, novel LPS inhibitors produced by marine bacterium. Journal of Antibiotics, 2016,70(1):79-83. doi: 10.1038/ja.2016.81 pmid: 27381520

[33]	Li H Y, Matsunaga S, Fusetani N . Halicylindramides A-C, antifungal and cytotoxic depsipeptides from the marine sponge Halichondria cylindrata. Journal of Medicinal Chemistry, 1995,51(8):338-343. doi: 10.1016/0040-4020(94)01097-J pmid: 7830276

[34]	Youssef D T, Shaala L A, Mohamed G A , et al. Theonellamide G, a potent antifungal and cytotoxic bicyclic glycopeptide from the Red Sea marine sponge Theonella swinhoei. Marine Drugs, 2014,12(4):1911-1923. doi: 10.3390/md12041911 pmid: 24694570

[35]	Zhang X, Jacob M R, Rao R R . Antifungal cyclic peptides from the marine sponge microscleroderma herdmani. Res Rep Med Chem, 2012,2:7-14 doi: 10.1055/s-0032-1307625 pmid: 3738201

[36]	Niggemann J, Bozko P, Bruns N , et al. Baceridin, a cyclic hexapeptide from an epiphytic Bacillus strain, inhibits the proteasome. Chembiochem, 2014,15(7):1021-1029. doi: 10.1002/cbic.201300778 pmid: 24692199

[37]	Ishihara K, Sobue M, Uemura D , et al. N -acetylgalactosamine 4,6-bissulfate in rat urine I. Isolation, identification and chemical synthesis. Biochimica Et Biophysica Acta, 1976,437(2):416-430. doi: 10.1016/0304-4165(76)90011-8 pmid: 952926

[38]	Kohli R M, Walsh C T, Burkart M D . Biomimetic synthesis and optimization of cyclic peptide antibiotics. Nature, 2002,418(6898):658-661. doi: 10.1038/nature00907 pmid: 12167866

[39]	Von D H, Dieckmann R, Pavela-Vrancic M . The nonribosomal code. Chemistry & Biology, 1999,6(10):273-279.

[40]	And Q X, Pei D . High-Throughput synthesis and screening of cyclic peptide antibiotics. Journal of Medicinal Chemistry, 2007; 50(13):3132-3137. doi: 10.1021/jm070282e pmid: 2527969

[41]	Oddo A, Thomsen T T, Britt H M , et al. Modulation of backbone flexibility for effective dissociation of antibacterial and hemolytic activity in cyclic peptides. Acs Medicinal Chemistry Letters, 2016,7(8):741-745. doi: 10.1021/acsmedchemlett.5b00400 pmid: 27563396

[42]	Abraham T, Prenner E J, Lewis R N , et al. Structure-activity relationships of the antimicrobial peptide gramicidin S and its analogs: aqueous solubility, self-association, conformation, antimicrobial activity and interaction with model lipid membranes. Biochimica et Biophysica acta, 2014,1838(5):1420-1429. doi: 10.1016/j.bbamem.2013.12.019

[43]	Oh D, Sun J, Nasrolahi S A , et al. Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens. Molecular Pharmaceutics, 2014,11(10):3528-3536. doi: 10.1021/mp5003027 pmid: 4186684

[44]	Falanga A, Nigro E ,De Biasi M G, , et al. Cyclic peptides as novel therapeutic microbicides: engineering of human defensin mimetics. Molecules, 2017,22(7):1217. doi: 10.3390/molecules22071217 pmid: 28726740

[45]	Scudiero O, Nigro E, Cantisani M , et al. Design and activity of a cyclic mini-β-defensin analog: a novel antimicrobial tool. International Journal of Nanomedicine, 2015,10:6523-6539. doi: 10.2147/IJN.S89610 pmid: 4610797

[46]	Sun L, Zheng C, Webster T J . Self-assembled peptide nanomaterials for biomedical applications: promises and pitfalls. International Journal of Nanomedicine, 2017,12:73-86. doi: 10.2217/nnm-2016-0316 pmid: 27876448

[47]	Clark T D , And L K B, Ghadiri M R. Self-assembling cyclic β3-peptide nanotubes as artificial transmembrane ion channels. Journal of the American Chemical Society, 1998,120(4):651-656. doi: 10.1021/ja972786f

[48]	Fernandezlopez S, Kim H S, Choi E C , et al. Antibacterial agents based on the cyclic d,l-\|[alpha]\|-peptide architecture. Nature, 2001,412(6845):452-455. doi: 10.1038/35086601

[49]	Zorzi A, Deyle K, Heinis C . Cyclic peptide therapeutics: past, present and future. Current Opinion in Chemical Biology, 2017,38:24-29. doi: 10.1016/j.cbpa.2017.02.006 pmid: 28249193

[50]	Cetinkaya Y, Falk P, Mayhall C G . Vancomycin-resistant enterococci. Clinical Microbiology Reviews, 2000,13(4):686-707. doi: 10.1128/CMR.13.4.686

[51]	Reynolds P E . Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Clinical Microbiology, 1989,8(11):943-950. doi: 10.1007/BF01967563 pmid: 2532132

[52]	Wijesekara P N K, Kumbukgolla W W, Jayaweera J , et al. Review on usage of vancomycin in livestock and humans: maintaining its efficacy, prevention of resistance and alternative therapy. Vet Sci, 2017,4(1):6. doi: 10.3390/vetsci4010006 pmid: 29056665

[53]	Klinker K P, Borgert S J . Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther, 2015,37(12):2619-2636. doi: 10.1016/j.clinthera.2015.11.007 pmid: 26658277

[54]	Patel S, Ahmed S, Eswari J S . Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles. World Journal of Microbiology & Biotechnology, 2015,31(8):1177-1193. doi: 10.1007/s11274-015-1880-8 pmid: 26041368

[55]	Srinivas N, Jetter P, Ueberbacher B J , et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science, 2010,327(5968):1010-1013. doi: 10.1126/science.1182749 pmid: 20167788

[1]	TANG Xin,MAO Xin-fang,MA Bin-yun,GOU Ping. Antimicrobial Peptides: Current Status and Future Challenges[J]. China Biotechnology, 2019, 39(8): 86-94.

[2]	LIU Xiao-ming, JIANG Ning, ZHANG Ai-zhong, CAI Peng. Expression of Hybrid Antimicrobial Peptides in Pichia Yeast and Identification of Its Biological Activity[J]. China Biotechnology, 2016, 36(2): 81-89.

[3]	WU Chun-xu, LU Xue-mei, JIN Xiao-bao, ZHU Jia-yong. Advances in Research on Molecular Design of Cecropin-like Peptides[J]. China Biotechnology, 2016, 36(2): 96-100.

[4]	LI Jian-bo, JIANG Ming-feng, WANG Yong. Tibetan Sheep Mammary Gland Lysozyme: Molecular Cloning, Prokaryotic Expression and Its Antibacterial Activity[J]. China Biotechnology, 2013, 33(8): 38-44.

[5]	MING Fei-ping, YANG Jun, ZHU Jin-mei, KUANG Zhe-shi, LI Hua-zhou, XIA Feng-geng, YE Ming-qiang, WANG Hou-guang, ZHAO Xiang-jie, HUANG Zhi-feng, MA Miao-peng, SHI Ju-qing, CAI Hai-ming, ZHANG Ling-hua. Modification of 5’UTR Sequences of pPIC9K Increases Expression of Antimicrobial Peptide PR39[J]. China Biotechnology, 2013, 33(12): 86-91.

[6]	ZHOU Guang-qi, MA Peng-bo, LIU Qiao, QUAN Chun-shan, FAN Sheng-di. *Optimization of Culture Medium and Prediction of Antibacterial Activity by Bacillus Amyloliquefaciens* Q-426 Fermentation**[J]. China Biotechnology, 2013, 33(11): 21-26.

[7]	XIONG Wen, YANG Xue-min, WANG Jian-hua, QUAN Chun-shan, FAN Sheng-di. *Effects of DKPs on Gene Expression of the Antibacterial Substances in Bacillus amyloliquefaciens* Q-426**[J]. China Biotechnology, 2012, 32(03): 47-52.

[8]	SHU Mei, XU Yang, XU Xi, TU Zhui. Expression and Activity Analysis of Two Anti-microbial Peptides from Aquatic Animals[J]. China Biotechnology, 2011, 31(02): 56-61.

[9]	. Antibacterial Cecropin and its application On Transgenic Plants for Bacterium Resistance[J]. China Biotechnology, 2008, 28(5): 122-127.

[10]	. Investigate antibiosis dynamics and antibacterial mechanisms of Antibacterial Peptides from Musca domestica Larvae[J]. China Biotechnology, 2006, 26(11): 33-39.

Viewed

Full text

Abstract

Cited

Shared

Discussed